Sort
48,018 grants matching “immunotherapy”
Bastyr/UW Oncomycology Translational Research Center
$1,147,443Leanna J Standish · Bastyr University · U19 · FY2010 · AT
EpCAM (CD326) Function in Epithelial Cell Biology and Immunophysiology
$1,147,402Mark Udey · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
$1,147,325Steven Mark Albelda · University Of Pennsylvania · P01 · FY2014 · CA
SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma
$1,146,618Ming Yang · Mucommune, Llc · R44 · FY2025 · CA
Biomaterials-directed regenerative immunotherapies
$1,146,250Jennifer Hartt Elisseeff · Johns Hopkins University · DP1 · FY2021 · AR
Biomaterials-directed regenerative immunotherapies
$1,146,250Jennifer Hartt Elisseeff · Johns Hopkins University · DP1 · FY2023 · AR
Biomaterials-directed regenerative immunotherapies
$1,146,250Jennifer Hartt Elisseeff · Johns Hopkins University · DP1 · FY2020 · AR
Biomaterials-directed regenerative immunotherapies
$1,146,250Jennifer Hartt Elisseeff · Johns Hopkins University · DP1 · FY2019 · AR
Biomaterials-directed regenerative immunotherapies
$1,146,250Jennifer Hartt Elisseeff · Johns Hopkins University · DP1 · FY2022 · AR
SPORE in Skin Cancer
$1,146,135Meenhard Herlyn · Wistar Institute · P50 · FY2009 · CA
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
$1,146,076Stuart L Schreiber · Broad Institute, Inc. · U01 · FY2018 · CA
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
$1,146,075Stuart L Schreiber · Broad Institute, Inc. · U01 · FY2017 · CA
Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes
$1,145,972Scarlett L Gomez · University Of California, San Francisco · R01 · FY2020 · CA
Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging
$1,145,798Eric Kaldjian · Rarecyte, Inc. · R44 · FY2020 · CA
Regulation And Function Of Retroelements
$1,145,531Henry L. Levin · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2019 · HD
Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer
$1,145,470Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2020 · CA
Development of botulinum neurotoxin immunotherapy
$1,145,202James D. Marks · University Of California, San Francisco · U01 · FY2006 · AI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
$1,145,064Lloyd M Yu · Planet Biotechnology, Inc. · R01 · FY2013 · AI
OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA
$1,144,800University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · Defense Health Agency
TARGETING PRMT3-IGF2BP1 AXIS-MEDIATED EPITRANSCRIPTOMIC REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME IMMUNOTHERAPY RESISTANCE IN CCRCC
$1,144,500The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2025 · Defense Health Agency
CD40L BLOCKADE IN PEDIATRIC RENAL TRANSPLANTATION
$1,142,480Children'S Hospital Boston · U01 · FY2002 · AI
Myelodysplasia
$1,142,177Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL
Dendritic cells heterogeneity and function
$1,141,362Roxane Tussiwand · National Institute Of Dental & Craniofacial Research · ZIA · FY2020 · DE
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
$1,140,443Stuart L Schreiber · Broad Institute, Inc. · U01 · FY2019 · CA
Preclinical drug development in pancreatic cancer
$1,140,440Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA